Literature DB >> 10659481

Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial.

A Sood1, V Midha, N Sood, V Kaushal.   

Abstract

OBJECTIVE: To investigate the efficacy of azathioprine in treating patients with severe ulcerative colitis.
DESIGN: One-year, randomized, placebo-controlled trial.
SUBJECTS: 83 patients with severe ulcerative colitis were enrolled. Fifty patients who relapsed within two months on corticosteroid withdrawal were randomized into two groups. The azathioprine group received oral sulfasalazine (6-8 g/day), oral prednisolone (1 mg/Kg/day) and oral azathioprine (2 mg/Kg/day). The placebo group received oral sulfasalazine (6-8 g/day), oral prednisolone (1 mg/Kg/day) and placebo. Corticosteroids were tapered over 12-16 weeks.
RESULTS: Five patients (2 in azathioprine group, 3 in placebo group) dropped out of the study. Three patients in the azathioprine group had side effects. The number of patients going into complete remission and partial remission was not significantly different in the two groups. The proportion of relapses in the azathioprine group was lower than in the placebo group (p < 0.05).
CONCLUSIONS: In patients with ulcerative colitis, azathioprine had no effect in achieving remission, when given in combination with prednisolone; however, it lowers the proportion of relapses. Side effects like pancreatitis and hepatitis are mild and respond promptly to drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10659481

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  28 in total

1.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

2.  Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?

Authors:  S Ghosh; R Chaudhary; M Carpani; R J Playford
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 3.  Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?

Authors:  B E Sands
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 4.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

5.  Long term results of use of azathioprine in patients with ulcerative colitis in India.

Authors:  Ajit Sood; Vandana Midha; Neena Sood; Manu Bansal
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

Review 6.  Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.

Authors:  Sara Renna; Mario Cottone; Ambrogio Orlando
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.

Authors:  S Ardizzone; G Maconi; A Russo; V Imbesi; E Colombo; G Bianchi Porro
Journal:  Gut       Date:  2005-06-21       Impact factor: 23.059

Review 8.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Authors:  Antje Timmer; Petrease H Patton; Nilesh Chande; John W D McDonald; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-18

9.  Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry.

Authors:  Hai Yun Shi; Francis K L Chan; Wai Keung Leung; Michael K K Li; Chi Man Leung; Shun Fung Sze; Jessica Y L Ching; Fu Hang Lo; Steven W C Tsang; Edwin H S Shan; Lai Yee Mak; Belsy C Y Lam; Aric J Hui; Wai Hung Chow; Marc T L Wong; Ivan F N Hung; Yee Tak Hui; Yiu Kay Chan; Kam Hon Chan; Ching Kong Loo; Carmen K M Ng; Wai Cheung Lao; Marcus Harbord; Justin C Y Wu; Joseph J Y Sung; Siew C Ng
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

Review 10.  Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2.

Authors:  Satoshi Tanida; Tsutomu Mizoshita; Keiji Ozeki; Takahito Katano; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.